Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Crizotinib"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 5328
Tytuł:
Different effects of crizotinib treatment in two non-small cell lung cancer patients with SDC4::ROS1 fusion variants.
Autorzy:
Ohishi Y; Nihon University Itabashi Hospital, Tokyo, Japan.
Nakanishi Y; Division of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Hirotani Y; Division of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Suzuki A; Division of Pathology Laboratory, Nihon University Itabashi Hospital, Tokyo, Japan.
Tanino T; Division of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Nishimaki-Watanabe H; Division of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Kobayashi H; Division of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Nozaki F; Division of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Ohni S; Division of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Tang X; Division of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Hayashi K; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Nakagawa Y; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Shimizu T; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Tsujino I; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Takahashi N; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Gon Y; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Masuda S; Division of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Jan; Vol. 15 (1), pp. 89-93. Date of Electronic Publication: 2023 Dec 13.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Crizotinib*/pharmacology
Crizotinib*/therapeutic use
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; Ki-67 Antigen ; Protein Kinase Inhibitors/therapeutic use ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics ; Reactive Oxygen Species ; Syndecan-4/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer: Multicenter retrospective analysis in South Korea.
Autorzy:
Jeon DS; Department of Pulmonary and Critical Care Medicine, Nowon Eulji Medical Center, University of Eulji, Seoul, South Korea.
Park CK; Department of Pulmonary and Critical Care Medicine, Chonnam National University Hwasun hospital, Chonnam National University, Jeollanam-do, Republic of Korea.
Kim SJ; Department of Internal Medicine, Postech-Catholic Biomedical Engineering Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Park CK; Department of Pulmonary and Critical Care Medicine, Catholic University of Korean Yeouido Saint Mary's Hospital, Seoul, Korea.
Chang YS; Department of Internal Medicine, Yonsei University College of Medicine, 8th Floor Annex Building, Yongdong Severance Hospital, Seoul, Republic of Korea.
Jung CY; Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Lee SY; Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Lee SY; Division of Pulmonary and Critical Care Medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea.
Ryu JS; Department of Pulmonary and Critical Care Medicine, Inha University Hospital, Incheon, Republic of Korea.
Lee JE; Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
Lee KY; Department of Pulmonary Medicine, Konkuk University School of Medicine, Seoul, Republic of Korea.
Jang TW; Department of Internal Medicine, Kosin University Medical College, Pusan, Korea.
Jang SH; Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
Yoon SH; Department of Internal Medicine, School of Medicine, Pusan National University, Yangsan, Republic of Korea.
Lee SH; Division of Pulmonology, Institute of Chest Disease, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Choi CM; Department of Pulmonary and Critical Care Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim HR; Department of Pulmonary and Critical Care Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim YJ; Department of Pulmonary and Critical Care Medicine, Nowon Eulji Medical Center, University of Eulji, Seoul, South Korea.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (6), pp. 448-457. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Lung Neoplasms*/pathology
Carcinoma, Non-Small-Cell Lung*/pathology
Humans ; Male ; Middle Aged ; Female ; Crizotinib/therapeutic use ; Anaplastic Lymphoma Kinase/therapeutic use ; Receptor Protein-Tyrosine Kinases/therapeutic use ; Protein Kinase Inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Autorzy:
Zhao, Mingye (AUTHOR)
Shao, Taihang (AUTHOR)
Shao, Hanqiao (AUTHOR)
Zhou, Caicun (AUTHOR)
Tang, Wenxi (AUTHOR)
Pokaż więcej
Źródło:
BMC Cancer. 2/8/2024, Vol. 24 Issue 1, p1-15. 15p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET.
Autorzy:
Xia S; Department of Respiratory Medicine, The Second Hospital, Dalian Medical University, Dalian, China.
Duan W; Department of Respiratory Medicine, The Second Hospital, Dalian Medical University, Dalian, China.
Xu M; Department of Respiratory Medicine, The Second Hospital, Dalian Medical University, Dalian, China.
Li M; Department of Respiratory Medicine, The Second Hospital, Dalian Medical University, Dalian, China.
Tang M; Department of Respiratory Medicine, The Second Hospital, Dalian Medical University, Dalian, China.
Wei S; Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Lin M; Department of Respiratory Medicine, The Second Hospital, Dalian Medical University, Dalian, China.
Li E; Department of Respiratory Medicine, The Second Hospital, Dalian Medical University, Dalian, China. .
Liu W; Department of Respiratory Medicine, The Second Hospital, Dalian Medical University, Dalian, China. .; Department of Scientific Research Center, The Second Hospital, Dalian Medical University, Dalian, China. .
Wang Q; Department of Respiratory Medicine, The Second Hospital, Dalian Medical University, Dalian, China. .; Department of Scientific Research Center, The Second Hospital, Dalian Medical University, Dalian, China. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Apr 03; Vol. 43 (1), pp. 103. Date of Electronic Publication: 2024 Apr 03.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Brain Neoplasms*/pathology
Benzamides*
Imidazoles*
Triazines*
Humans ; Animals ; Mice ; Mesothelin ; GPI-Linked Proteins/metabolism ; Crizotinib ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
Autorzy:
Terrones M; Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research, University of Antwerp and Antwerp University Hospital, Wilrijk, Belgium.
Deben C; Center for Oncological Research, University of Antwerp and Antwerp University Hospital, Wilrijk, Belgium.
Rodrigues-Fortes F; Center for Oncological Research, University of Antwerp and Antwerp University Hospital, Wilrijk, Belgium.
Schepers A; Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research, University of Antwerp and Antwerp University Hospital, Wilrijk, Belgium.
de Beeck KO; Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research, University of Antwerp and Antwerp University Hospital, Wilrijk, Belgium.
Van Camp G; Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research, University of Antwerp and Antwerp University Hospital, Wilrijk, Belgium.
Vandeweyer G; Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Mar 03; Vol. 22 (1), pp. 234. Date of Electronic Publication: 2024 Mar 03.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Pyrazoles*
Sulfones*
Benzamides*
Aminopyridines*
Indazoles*
Lactams*
Pyrimidines*
Humans ; Protein-Tyrosine Kinases/genetics ; Crizotinib ; CRISPR-Cas Systems/genetics ; Proto-Oncogene Proteins ; Drug Resistance
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Development of 10-Hydroxycamptothecin-crizotinib conjugate based on the synergistic effect on lung cancer cells.
Autorzy:
Liu Z; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, P. R. China.
Xu Y; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, P. R. China.
Guo L; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, P. R. China.
Li X; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, P. R. China.
Gao J; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, P. R. China.
Xie W; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, P. R. China.
Zhao L; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, P. R. China.
Teng Y; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, P. R. China.
Li X; Central Laboratory, Endocrine and Metabolic Disease Center, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Medical Key Laboratory of Hereditary Rare Diseases of Henan; Luoyang Sub-Center of National Clinical Research Center for Metabolic Diseases, Luoyang, P. R. China.
Yu P; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, P. R. China.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 1-11.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/drug therapy
Lung Neoplasms*/metabolism
Humans ; Crizotinib/pharmacology ; Crizotinib/therapeutic use ; Cell Line, Tumor ; Apoptosis ; ErbB Receptors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Association of anticoagulant use with clinical outcomes from crizotinib in ALK- and ROS1-rearranged advanced non-small cell lung cancers: A retrospective analysis of PROFILE 1001.
Autorzy:
Ng TL; Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, Canada.
Tsui DCC; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Wang S; Pfizer Oncology, San Francisco, California, USA.
Usari T; Pfizer, Milan, Italy.
Patil T; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Wilner K; Pfizer Oncology, La Jolla, California, USA.
Camidge DR; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2022 Dec; Vol. 11 (23), pp. 4422-4429. Date of Electronic Publication: 2022 May 05.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Crizotinib*/therapeutic use
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Humans ; Gene Rearrangement ; Protein Kinase Inhibitors/therapeutic use ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC).
Autorzy:
Fabbri, Laura (AUTHOR)
Di Federico, Alessandro (AUTHOR)
Astore, Martina (AUTHOR)
Marchiori, Virginia (AUTHOR)
Rejtano, Agnese (AUTHOR)
Seminerio, Renata (AUTHOR)
Gelsomino, Francesco (AUTHOR)
De Giglio, Andrea (AUTHOR)
Pokaż więcej
Źródło:
Diagnostics (2075-4418). Jan2024, Vol. 14 Issue 1, p48. 29p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical outcomes of ALK + non-small cell lung cancer in Denmark.
Autorzy:
Hansen KH; Department of Oncology, Odense University Hospital, Odense, Denmark.
Johansen JS; Department of Oncology, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
Urbanska EM; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Meldgaard P; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Hjorth-Hansen P; Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
Kristiansen C; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
Stelmach M; Department of Oncology, Næstved Hospital, Næstved, Denmark.
Santoni-Rugiu E; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Ulhøi MP; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Dydensborg AB; Takeda Pharma A/S, Copenhagen, Denmark.
Dünweber C; Takeda Pharma A/S, Copenhagen, Denmark.
Andersen JL; Department of Oncology, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
Pokaż więcej
Źródło:
Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2023 Dec; Vol. 62 (12), pp. 1775-1783. Date of Electronic Publication: 2023 Nov 25.
Typ publikacji:
Journal Article
MeSH Terms:
Anaplastic Lymphoma Kinase*/antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/mortality
Lung Neoplasms*/drug therapy
Lung Neoplasms*/epidemiology
Lung Neoplasms*/metabolism
Protein Kinase Inhibitors*/therapeutic use
Female ; Humans ; Middle Aged ; Crizotinib/therapeutic use ; Denmark/epidemiology ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 .
Autorzy:
Liu S; Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medicinal University (Foshan Maternity & Child Healthcare Hospital), Foshan, China.; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Huang C; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Huang C; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Huang Y; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Yu Y; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Wu G; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Guo F; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Jiang Y; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Wan S; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Zhu Z; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Tian Y; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Zhu J; Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medicinal University (Foshan Maternity & Child Healthcare Hospital), Foshan, China.
Zhang J; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2227779.
Typ publikacji:
Journal Article
MeSH Terms:
Protein-Tyrosine Kinases*
Lung Neoplasms*
Humans ; Anaplastic Lymphoma Kinase ; Drug Resistance, Neoplasm ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins/chemistry ; Crizotinib/pharmacology ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/chemistry ; Mutation ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC).
Autorzy:
Lee SY; Department of Biomedical Engineering, Gachon University, Seongnam, 13120, Republic of Korea.; Central R & D Center, Medical & Bio Decision (MBD) Co., Ltd, Suwon, 16229, Republic of Korea.
Cho HJ; Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Choi J; Central R & D Center, Medical & Bio Decision (MBD) Co., Ltd, Suwon, 16229, Republic of Korea.
Ku B; Central R & D Center, Medical & Bio Decision (MBD) Co., Ltd, Suwon, 16229, Republic of Korea.
Moon SW; Department of Thoracic and Cardiovascular Surgery, College of Medicine, The Catholic University of Korea, Seoul, 06591, Korea.
Moon MH; Department of Thoracic and Cardiovascular Surgery, College of Medicine, The Catholic University of Korea, Seoul, 06591, Korea.
Kim KS; Department of Thoracic and Cardiovascular Surgery, College of Medicine, The Catholic University of Korea, Seoul, 06591, Korea.
Hyun K; Department of Thoracic and Cardiovascular Surgery, College of Medicine, The Catholic University of Korea, Seoul, 06591, Korea.
Kim TJ; Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, 06591, Korea.
Sung YE; Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, 06591, Korea.
Hwang Y; Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Lee E; Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Ahn DH; Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Choi JY; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Lim JU; Division of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Park CK; Division of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Kim SW; Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Kim SJ; Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Postech-Catholic Biomedical Engineering Institute, College of Medicine, The Catholic University of Korea, Songeui Multiplex Hall, Seoul, Republic of Korea.
Koo IS; Department of Biomedical Engineering, Gachon University, Seongnam, 13120, Republic of Korea.
Jung WS; Department of Biomedical Engineering, Gachon University, Seongnam, 13120, Republic of Korea.
Lee SH; Central R & D Center, Medical & Bio Decision (MBD) Co., Ltd, Suwon, 16229, Republic of Korea. .
Yeo CD; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. .
Lee DW; Department of Biomedical Engineering, Gachon University, Seongnam, 13120, Republic of Korea. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Nov 22; Vol. 42 (1), pp. 309. Date of Electronic Publication: 2023 Nov 22.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/diagnosis
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/diagnosis
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Humans ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Crizotinib/therapeutic use ; Organoids
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Crizotinib combined with bronchoscopic interventional treatment in ALK-positive inflammatory myofibroblastic tumor of left main stem bronchus: a case report.
Autorzy:
Zhang P; Department of Cardiothoracic Surgery, The 961st Hospital of Joint Logistics Support Force of PLA, Qiqihar, 230200, China.
Wang C; Department of Emergency and Critical Care Medicine, The 961st Hospital of Joint Logistics Support Force of PLA, Qiqihar, 230200, China.
Lv Z; Department of Pathology, Changzheng Hospital, Naval Medical University, Shanghai, 200040, China.
Du M; Department of Cardiothoracic Surgery, The 961st Hospital of Joint Logistics Support Force of PLA, Qiqihar, 230200, China.
Xu R; Department of Cardiothoracic Surgery, The 960th Hospital of Joint Logistics Support Force of PLA, No. 25 Shifan Road, Tianqiao District, Jinan, 250031, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of cardiothoracic surgery [J Cardiothorac Surg] 2023 Nov 10; Vol. 18 (1), pp. 318. Date of Electronic Publication: 2023 Nov 10.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Granuloma, Plasma Cell*/diagnosis
Granuloma, Plasma Cell*/drug therapy
Granuloma, Plasma Cell*/surgery
Male ; Humans ; Adolescent ; Crizotinib/therapeutic use ; Anaplastic Lymphoma Kinase/genetics ; Protein Kinase Inhibitors/therapeutic use ; Bronchi
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan.
Autorzy:
Wang HS; Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan.
Liu CY; Department & Centers of Lung Cancer and Interventional Bronchoscopy, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan.
Hsu SC; Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan.
Huang SC; Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan.
Hung TH; Institute of Stem Cell & Translational Cancer Research, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan 33305, Taiwan.
Ng KF; Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan.
Chen TC; Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 May 21; Vol. 23 (10). Date of Electronic Publication: 2022 May 21.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Crizotinib*/therapeutic use
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Protein-Tyrosine Kinases*/genetics
Protein-Tyrosine Kinases*/metabolism
Proto-Oncogene Proteins*/genetics
Proto-Oncogene Proteins*/metabolism
Translocation, Genetic*
ErbB Receptors/genetics ; Humans ; In Situ Hybridization, Fluorescence ; Oncogenes ; Prospective Studies ; Retrospective Studies ; Taiwan/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.
Autorzy:
Jóri B; Lungenkrebsmedizin Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany.; Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
Vössing C; Lungenkrebsmedizin Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany.; Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
Pirngruber J; Lungenkrebsmedizin Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany.; Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
Willing EM; Lungenkrebsmedizin Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany.; Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
Arndt K; Lungenkrebsmedizin Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany.; Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
Falk M; Lungenkrebsmedizin Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany.; Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
Tiemann M; Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
Heukamp LC; Lungenkrebsmedizin Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany.; Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
Hoffknecht P; Lungenkrebsmedizin Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany.; Department of Thorax Oncology, Niels-Stensen-Kliniken, Franziskus-Hospital Harderberg Alte, Rothen-Felder Straße 23, 49124 Georgsmarienhütte, Germany.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Sep 27; Vol. 30 (10), pp. 8805-8814. Date of Electronic Publication: 2023 Sep 27.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; Male ; Middle Aged ; Crizotinib/therapeutic use ; Drug Resistance, Neoplasm/genetics ; ErbB Receptors/genetics ; Mutation ; Protein Kinase Inhibitors/adverse effects ; Proto-Oncogene Proteins c-met/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR -Mutated NSCLC.
Autorzy:
Urbanska EM; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.
Grauslund M; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.
Koffeldt PR; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.
Truelsen SLB; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.
Löfgren JO; Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.
Costa JC; Department of Radiology, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.
Melchior LC; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.
Sørensen JB; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Santoni-Rugiu E; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Aug 23; Vol. 24 (17). Date of Electronic Publication: 2023 Aug 23.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Tyrosine Kinase Inhibitors*/pharmacology
Humans ; Crizotinib/therapeutic use ; ErbB Receptors/genetics ; In Situ Hybridization, Fluorescence ; Proto-Oncogene Proteins c-met/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Epithelial cell adhesion molecule (EpCAM) regulates HGFR signaling to promote colon cancer progression and metastasis.
Autorzy:
Lee, Chi-Chiu (AUTHOR)
Yu, Chia-Jui (AUTHOR)
Panda, Sushree Shankar (AUTHOR)
Chen, Kai-Chi (AUTHOR)
Liang, Kang-Hao (AUTHOR)
Huang, Wan-Chen (AUTHOR)
Wang, Yu-Shiuan (AUTHOR)
Ho, Pei-Chin (AUTHOR)
Wu, Han-Chung (AUTHOR)
Pokaż więcej
Źródło:
Journal of Translational Medicine. 8/5/2023, Vol. 21 Issue 1, p1-22. 22p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Autorzy:
Zheng B; Department of Pharmacy, Tongde Hospital Zhejiang Province, Hangzhou, China.; Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China.
Jiang H; Department of Pharmacy, Tongde Hospital Zhejiang Province, Hangzhou, China.; Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China.
Yang W; Department of Pharmacy, Tongde Hospital Zhejiang Province, Hangzhou, China.; Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China.
Li Y; Department of Pharmacy, Tongde Hospital Zhejiang Province, Hangzhou, China.; Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China.
Liang B; Department of Pharmacy, Tongde Hospital Zhejiang Province, Hangzhou, China.; Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China.
Zhu J; Department of Pharmacy, Tongde Hospital Zhejiang Province, Hangzhou, China.; Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China.
Chen N; Department of Pharmacy, Tongde Hospital Zhejiang Province, Hangzhou, China.; Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China.
Chen M; Department of Pharmacy, Tongde Hospital Zhejiang Province, Hangzhou, China.; Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China.
Zhang M; Department of Pharmacy, Tongde Hospital Zhejiang Province, Hangzhou, China.; Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (15), pp. 15983-15997. Date of Electronic Publication: 2023 Jun 19.
Typ publikacji:
Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Brain Neoplasms*/secondary
Humans ; Crizotinib/therapeutic use ; Network Meta-Analysis ; Bayes Theorem ; Anaplastic Lymphoma Kinase/genetics ; Protein Kinase Inhibitors/adverse effects ; Carbazoles/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.
Autorzy:
Miao K; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhang X; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Wang H; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Si X; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhang L; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2023 May; Vol. 14 (13), pp. 1162-1170. Date of Electronic Publication: 2023 Mar 21.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Crizotinib/therapeutic use ; Retrospective Studies ; Cross-Sectional Studies ; Mutation ; Proto-Oncogene Proteins c-met/genetics ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 5328

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies